Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yu. B. Kochkareva"'
Autor:
M. M. Bobkova, S. V. Semochkin, V. L. Ivanova, O. G. Agafonova, L. A. Antipova, N. N. Volchenko, V. V. Dergacheva, O. D. Zacharov, Yu. A. Kudinov, S. S. Kulikova, Yu. B. Kochkareva, N. A. Lobanova, I. E. Lazarev, E. V. Laricheva, L. A. Magomedova, N. V. Malachova, V. G. Markaryan, L. A. Mucha, S. V. Minenko, T. Yu. Ostrenkova, E. V. Ovanesova, T. N. Perestoronina, M. E. Ribakova, E. A. Samischina, V. V. Ptuschkin
Publikováno v:
Онкогематология, Vol 0, Iss 4, Pp 4-11 (2022)
Analysis of treatment results of 165 primary adult patients with diffuse B large-cells lymphoma (DBLCL) treating in Moscow municipal clinics is presented. Study aimed on analysis of efficacy of various dose intensity chemotherapy schedule according t
Externí odkaz:
https://doaj.org/article/aab1cc29558b433db499301fc239c159
Autor:
S. V. Semochkin, E. G. Arshanskaya, O. D. Zakharov, A. N. Kotelnikova, S. S. Kulikova, E. V. Ovanesova, Yu. B. Kochkareva, V. L. Ivanova
Publikováno v:
Онкогематология, Vol 10, Iss 1, Pp 16-23 (2015)
Efficacy and safety results of rituximab and bendamustine combination (Scheme BR) in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) are presented. From 01.2012 to 04.2013, the treatment was initiated in 43 patients (21 with
Externí odkaz:
https://doaj.org/article/dcd775da76264d68be7f28f9c505a29f
Autor:
E. E. Markova, E. A. Nikitin, E. A. Dmitrieva, S. Yu. Mayorоva, Yu. B. Kochkareva, E. V. Naumova, S. A. Lugovskaya, M. E. Pochtar, А. А. Petrenko, М. I. Kislova, B. V. Biderman, А. B. Sudarikov, Т. N. Obukhova, V. V. Ptushkin
Publikováno v:
Russian journal of hematology and transfusiology. 67:478-490
Introduction. Optimal therapy for elderly patients with chronic lymphocytic leukemia (CLL) is the subject of intensive research.Aim – to study the safety of obinutuzumab, as well as the selection of the optimal scheme of its use in patients with CL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45cc9eac56b42009bfd45ddbc9e487de
https://doi.org/10.35754/0234-5730-2022-67-4-478-490
https://doi.org/10.35754/0234-5730-2022-67-4-478-490
Autor:
S. A. Kardanova, Yu. Yu. Kirichenko, O. V. Bochkarnikova, O. N. Antyufeeva, Yu. B. Kochkareva, O. Yu. Vinogradova, E. V. Privalova, I. S. Ilgisonis, Yu. N. Belenkov
Publikováno v:
Kardiologiia. 62(9)
Aim To evaluate in a pilot study time-related changes in the clinical state, indexes of the acute phase of inflammation, parameters of blood lipid profile, intracardiac hemodynamics, and disorders of cardiac rhythm/conduction in patients who are not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b6955c30c0486bf8acc1d34bf3f6575
https://pubmed.ncbi.nlm.nih.gov/36206134
https://pubmed.ncbi.nlm.nih.gov/36206134
Autor:
Yu N Belenkov, D. A. Budanova, O. V. Bochkarnikova, I. Yu. Gadaev, Yu B Kochkareva, Yu Yu Kirichenko, V. I. Ershov, O N Antyufeeva, I. Ya. Sokolova
Publikováno v:
Kardiologiia. 59:47-53
Purpose: to study dynamics of indicators of oxidative stress and their role in development of cardiotoxicity in patients with lympho-proliferative diseases at the background of polychemotherapy. Materials and methods . We included into this study 30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b647891e0ebcfd893fcb3fb788cdf39
https://doi.org/10.18087/cardio.2019.8.n682
https://doi.org/10.18087/cardio.2019.8.n682
Publikováno v:
Терапевтический архив, Vol 91, Iss 7, Pp 83-92 (2019)
To study the epidemiology of multiple myeloma in the city of Moscow and compare the results obtained with data from similar studies in other countries.The study is based on information from a database of case histories of 3942 patients suffering from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ce426dce72e54dd4c378c9920af6e2
https://doi.org/10.26442/00403660.2019.07.000305
https://doi.org/10.26442/00403660.2019.07.000305
Publikováno v:
Терапевтический архив, Vol 82, Iss 2, Pp 59-61 (2010)
The use of imatinib mesylate (Glivec®) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is general
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::cee594315c53046c048940dc2c67f2b7
https://ter-arkhiv.ru/0040-3660/article/view/30558
https://ter-arkhiv.ru/0040-3660/article/view/30558
Publikováno v:
Терапевтический архив, Vol 91, Iss 7, Pp 83-92 (2019)
Aim. To study the epidemiology of multiple myeloma in the city of Moscow and compare the results obtained with data from similar studies in other countries. Materials and methods. The study is based on information from a database of case histories of
Externí odkaz:
https://doaj.org/article/dd3ff25b79ae4c45a096b206c30392b8